Regulus Therapeutics Inc. - Common Stock (RGLS)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareholders. Under the terms of the proposed transaction, Regulus shareholders will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus’ lead product candidate, farabursen.

The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis.

Lately, several enterprises have surfaced in the media spotlight for various reasons, potentially catching the eye of investors. This article offers an in-depth examination of five companies that could be worthwhile to monitor.

Regulus Therapeutics Inc. (NASDAQ: RGLS) is one today’s most active stocks by volume. So far today, approximately 76.96M shares of Regulus Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 54,867 shares.